Cross-Sector entity
Eli Lilly is the most frequent co-covered peer, appearing in 8 of the 8 tracked stories. That works out to roughly 0.5 stories per week across a 122-day span. The busiest single day carried 3. Coverage clusters in clinical-trial, which accounts for 3 of those 8, with the remainder spread across 3 other categories.
8 verified stories tracked
Last mentioned: Jun 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Eli Lilly is the most frequent co-covered peer, appearing in 8 of the 8 tracked stories. That works out to roughly 0.5 stories per week across a 122-day span. The busiest single day carried 3. Coverage clusters in clinical-trial, which accounts for 3 of those 8, with the remainder spread across 3 other categories. We currently track 8 Cross-Sector stories that mention Retatrutide, published between February 24, 2026 and June 25, 2026. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment.
Computed from the 8 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Retatrutide. Shared-story counts are live from our verified record — not editorial picks.
Regulatory Submissions
Expected window for the first triple-agonist drug applications to the FDA.
STAT News publishes exposé
Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap.
White House denial
Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity.
Compassionate use request submitted
A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
Novo Triple-G Phase 2
Novo Nordisk reports nearly 20% weight loss at 26 weeks.
Phase 3 Expansion
Anticipated start of Novo Nordisk's pivotal late-stage clinical program.
Lilly Retatrutide Phase 2
Eli Lilly releases data showing 17.5% weight loss at 24 weeks.
The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments.
Source: Josh Marcus (gb) · Kevin Frey (us)
RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments.
Source: insidermonkey.com · finance.yahoo.com
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
Source: Endpoints News · Endpoints News
Novo Nordisk's experimental triple-G agonist demonstrated nearly 20% weight loss in a 26-week Phase 2 trial, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's mid-stage results, Novo remains on track to reach the market after its rival.
Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.
Source: Endpoints News · Endpoints News
